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doi:10.1016/j.jtcvs.2006.07.042bjectives: Cyclooxygenase-2 is associated with cardiac hypertrophy during chronic
eart failure and is regulated through the PI3K/Akt pathway. Cyclooxygenase-2-
nduced cell growth through Akt phosphorylation was demonstrated in vitro. In chronic
eart failure, left ventricular assist devices lead to hypertrophy regression and molecular
hanges. Therefore, the expression of cyclooxygenase-2, phosphorylated Akt (p-Akt),
nd p-Erk 1/2, as well as cardiac hypertrophy before and after left ventricular assist
evice insertion, was investigated.
ethods: In myocardial tissue before and after left ventricular assist device inser-
ion, the expression of cyclooxygenase-2, p-Akt (Thr308), p-Akt (Ser473), and p-Erk 1/2
as demonstrated by immunohistochemistry and quantified by morphometry. Co-
ocalization of cyclooxygenase-2 and p-Akt (Thr308) was investigated by immuno-
oublestaining.
esults: A significant decrease of cyclooxygenase-2, p-Akt (Thr308), p-Akt (Ser473), and
-Erk 1/2 protein expression and hypertrophy regression was observed after left ven-
ricular assist device insertion. A significant correlation between cyclooxygenase-2 and
-Akt (Thr308) expression, as well as between cyclooxygenase-2 expression and
ardiomyocyte diameter, was observed before, but not after, left ventricular assist
evice insertion. Only cyclooxygenase-2-positive cardiomyocytes showed sig-
ificant hypertrophy regression on unloading. Sarcoplasmic colocalization of
yclooxygenase-2 and p-Akt (Thr308) is present before left ventricular assist
evice insertion and is decreased after unloading, whereas the normal myocar-
ium is completely devoid of it.
onclusions: Left ventricular assist device treatment is associated with a significant
ecrease of cyclooxygenase-2, p-Akt (Thr308), p-Akt (Ser473), and p-Erk 1/2, and
ardiac hypertrophy regression of cyclooxygenase-2-positive cardiomyocytes. The
ignificant correlation and colocalization in cardiomyocytes of cyclooxygenase-2
nd p-Akt (Thr308) before left ventricular assist device insertion suggests a cross-talk
etween the 2 molecules in the progression of cardiac hypertrophy, which is
eversibly regulated by the left ventricular assist device.
hen various stimuli impose increased biomechanical stress, the myocar-
dium reacts by enlarging individual cardiomyocytes, resulting in hyper-
trophy. Although salutary at the beginning by normalizing wall tension,
his condition ultimately instigates an unfavorable outcome with progression to
hronic heart failure (CHF) or sudden cardiac death. In response to diverse load
onditions, cardiomyocytes undergo hypertrophy or apoptosis (“cardiac remodeling”).1
he only curative treatment for terminal CHF is cardiac transplantation. Left ventricular
ssist devices (LVADs) are used to support patients until transplantation and/or to
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CSPestore basic cardiac function.2 LVADs lead to decreased car-
iac size and dilation,3 reflected by decreased cardiomyocyte
iameters,4-6 length, and volume.6 Moreover, there are changes
f molecular systems involved in cardiomyocyte growth and
poptosis (“reverse remodeling”).7
CHF is associated with the induction of inflammatory
actors including prostanoids, which exert diverse func-
ional and morphologic effects on cardiomyocytes. Prosta-
oids (prostaglandins and thromboxane A2) are the meta-
olic products of arachidonic acid via the cyclooxygenase
COX) pathway. Today, 3 forms of COX are recognized:8
1) constitutive COX-1; (2) COX-3, an alternatively spliced
orm of COX-1; and (3) COX-2, which is rapidly induced in
esponse to various stimuli including cytokines9 such as
umor necrosis factor- and hypoxia,10 both considered
allmarks of CHF.11 Consequentially, increased expression
f COX-2 was demonstrated in the failing myocardium.12
OX-2 expression is regulated through multiple signaling
athways,13 including the PI3K/Akt pathway, which has
merged as a major player in cell growth and apoptosis.14
verexpression of COX-2-induced Akt phosphorylation at
hr308, but not at Ser473, was demonstrated in vitro, indi-
ating that the COX-2-induced growth stimulus is mediated
ainly by phosphoinositide-dependent protein kinase-1–
ontrolled Akt phosphorylation.15 Akt itself was suggested 
s a promoter of cardiac hypertrophy.16
The aim of this study was to investigate whether COX-2 is
eversibly regulated in CHF by LVADs. Moreover, the roles of
hosphorylated Akt (p-Akt) and Er k 1/2 in the regulation of
OX-2 were analyzed in both CHF and “reverse remodeling.”
ecause both COX-2 and Akt are involved in cardiomyocyte
rowth, the correlation between these proteins and cardiac
ypertrophy was determined, and a potential colocalization
as investigated by immuno-doublestaining.
aterials and Methods
atients
total of 35 patients (25 patients with Novacor N100; Baxter
ealthcare Corporation, Novacor Division, Oakland, Calif; 3 pa-
ients with Heartmate 1000 IP, Thermo Cardiosystems Inc,
oburn, Mass; and 7 patients with MicroMed DeBakey axial flow
ump system, MicroMed Technologies Inc, Woodlands, Tex) who
nderwent LVAD implantation for end-stage CHF as a bridge to
ransplantation were investigated. Dilated cardiomyopathy was
iagnosed in 20 patients, 13 with ischemic cardiomyopathy, 1 with
yocarditis, and 1 with congenital heart disease (tetralogy of
Abbreviations and Acronyms
CHF  chronic heart failure
COX  cyclooxygenase
LVAD left ventricular assist deviceallot). The patients’ mean age was 43.55 years (median: 46 years; s
8 The Journal of Thoracic and Cardiovascular Surgery ● Januaange: 18-58 years). The mean duration of LVAD implantation
as 167.86 days (median: 164 days; range: 14-298 days). Six
ealthy donor hearts that were not used for transplantation served
s controls.
etermination of Cardiomyocyte Diameter
lides of each individual tissue removed at the time of LVAD
mplantation (before LVAD from the cardiac apex) and at the time
f transplantation (after LVAD from the ventricular wall cranial to
he apex to avoid sampling of scar tissue) were stained with
eriodic acid-Schiff reaction. With an image analysis program (KS
00, Zeiss, Oberkochen, Germany), the diameters of at least 100
ardiomyocytes were determined in randomly selected visual
elds at a 400-fold magnification.
Moreover, the diameters of COX-2–positive and negative car-
iomyocytes were selectively determined before and after LVAD
mplantation in randomly chosen myocardial regions.
mmunohistochemistry and Morphometric Evaluation
f COX-2, p-Akt, and p-Erk 1/2
-m-thick sections of formalin-fixed and paraffin-embedded tis-
ues were dewaxed and rehydrated according to standard proce-
ures. The specimens were heated in citric acid buffer at 97°C for
ntigen retrieval and incubated with monoclonal antibodies di-
ected against COX-2 (monoclonal antibody, DCS, Hamburg, Ger-
any), p-Akt Thr308, p-Akt Ser473 (polyclonal antibodies, Santa
ruz Biotechnology, Santa Cruz, Calif), and p-Erk 1/2 (polyclonal
ntibody, Cell Signalling, Cummings). For COX-2, cardiomyo-
ytes were considered positive when a moderate to strong cyto-
lasmic staining was observed. For p-Akt (Thr308 and Ser473),
ardiomyocytes were considered positive when there was a mod-
rate to strong nuclear staining or both nuclear and cytoplasmic
taining. Cardiomyocytes with a moderate to strong nuclear stain-
ng for p-Erk 1/2 were regarded as positive.
With an image analysis program, the numeric density of pos-
tive cells per visual field with a defined size was determined
ollowing the rules of the forbidden and permitted lines. Counts
ere selectively performed in subepicardial, midmyocardial, and
ubendocardial areas in 7 randomly selected visual fields in each
rea and patient.
mmunofluorescence Doublestaining of COX-2 and
-Akt (Thr308)
ewaxed slides were treated for antigen retrieval as described
bove, incubated with antibodies against COX-2 and
-Akt (Thr308), and visualized by secondary antibodies coupled
o Cy3 and fluorescein isothiocyanate, respectively. Nuclei
ere highlighted by DAPI. Lipofuscin pigments were removed
y application of a Sudan black B stain to avoid autofluores-
ence. Colocalization of COX-2 and p-Akt (Thr308) was inves-
igated by laser scan microscopy (Zeiss LSM 510, Carl Zeiss
nc, Thornwood, NY) using appropriate filters.
tatistical Analysis
ll data were analyzed and expressed as mean  standard error of
he mean and depicted as box plots. For evaluation of statistical
ignificance, the nonparametric Wilcoxon test for paired samples
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Pnd bivariate correlation analysis according to Spearman were
sed (Statistical Package for the Social Sciences, SPSS Inc, Chi-
ago, Ill). Intergroup differences between the groups and controls
ere calculated by one-way analysis of variance followed by post
oc analysis according to Duncan.
esults
ardiomyocyte Diameter
significant decrease of general cardiomyocyte diameter
as observed after mechanical support (P  .009) as cal-
ulated by the nonparametric Wilcoxon test (Figure 1, A).
he mean cardiomyocyte diameter was 21.25 m (median:
0.84 m; range: 4.88-33.01 m) before LVAD insertion
nd decreased to a mean diameter of 19.39 m (median:
8.86 m; range: 9.95-30.46 m) with unloading. The
ean diameter of the controls was 15.56 m (median: 16.72
m; range: 10.99-18.05 m). However, when post hoc
esting according to Duncan was applied, the differences in
iameters between tissues obtained before and after LVAD
mplantation were not significant. When specifically compar-
Figure 1. Significant decrease of cardiomyocyte diame
(left). Significant difference between post-LVAD spec
analysis according to Duncan (right). Data (box plots).
Note that cardiomyocyte diameters after LVAD insert
decrease of COX-2–positive cardiomyocytes after LVA
2–negative cardiomyocytes before and after LVAD ins
cardiomyocytes with expression of COX-2 (C) and p-A
Data (box plots). Outliers (circles). Significant differenng the diameters of COX-2–positive cardiomyocytes before L
The Journal of Thoracnd after unloading, a significant decrease was observed (P 
016), whereas the COX-2–negative cardiomyocyte diameters
ere not significantly decreased (Figure 1, B). The mean
iameter of COX-2–positive cardiomyocytes before LVAD
nsertion was 23.06 m (median: 22.18 m; range: 15.57-
3.01 m) and decreased to 20.14 m after LVAD insertion
median: 19.27 m; range: 11.65-30.01 m), whereas the
ean diameter of COX-2–negative cardiomyocytes before
VAD insertion was 19.77 m (median: 19.07 m; range:
2.6-30.42 m) and regressed to 18.75 m after unloading
median: 18.48 m; range: 9.95-30.46 m).
umeric Density of COX-2–Positive Cardiomyocytes
significant decrease of COX-2–positive cardiomyocytes
P  .001) after LVAD insertion was observed. The mean
umber of COX-2–positive cardiomyocytes was 5.59 per
isual field (median: 5.45; range: 0.45-12.77) before LVAD
nsertion and decreased to 2.28 (median: 1.8; range: 0.15-
.7) after unloading (Figure 1, C). COX-2 expression after
y LVAD as calculated by nonparametric Wilcoxon test
s compared with controls as calculated by post hoc
ers (circles). Significant differences (horizontal bars).
emain higher than in control hearts (A). Significant
ertion (left). No significant difference between COX-
n (right) (Wilcoxon test) (B). Significant decrease of
r308) (D) after LVAD insertion compared with controls.
horizontal bars).ter b
imen
Outli
ion r
D ins
ertio
kt (Th
ces (VAD support reached levels similar to the control hearts
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CSPs calculated by post hoc analysis (mean count: 0.85; me-
ian: 0.74; range: 0.0-1.77).
umeric Density of p-Akt (Thr308)-Positive
ardiomyocytes
he number of cardiomyocytes with posittive signals for
-Akt (Thr308) was significantly decreased after LVAD
nsertion (P  .001). The mean count of positive cardi-
myocytes was 3.76 per visual field (median: 3.6; range:
.1-8.3) before LVAD insertion and decreased to 2.31
median: 2.37; range: 0.10-4.25) after unloading. The
ean count in the controls was 2.87 (median: 2.47;
ange: 1.57-5.93) (Figure 1, D ). Post hoc analysis showed
decrease of p-Akt (Thr308) to the level of controls.
umeric Density of p-Akt (Ser473)-Positive
ardiomyocytes
he number of cardiomyocytes staining positively for
-Akt (Ser473) was significantly decreased after LVAD
nsertion (P  .001). The mean number of positive car-
iomyocytes was 3.98 per visual field (median: 3.97;
ange: 1.20-6.7) before LVAD insertion and decreased to
Figure 2. Significant decrease of cardiomyocytes with
insertion. Data (box plots). Outliers (circles). Significan
significantly reduced, does not decrease to the leve
Significant positive correlation between COX-2 and p-A
cardiomyocyte diameter before LVAD insertion (D)..61 (median: 2.45; range: 0.0-5.9) after LVAD insertion. i
0 The Journal of Thoracic and Cardiovascular Surgery ● Januahe mean count in the controls was 2.27 (median: 2.87;
ange: 0.33-3.77). Post hoc analysis demonstrated a de-
rease of p-Akt (Ser473) -positive cardiomyocytes to the
evel of controls (Figure 2, A ).
umeric Density of p-Erk 1/2-Positive Cardiac
yocytes
efore LVAD insertion, the mean density of cardiomyo-
ytes with positive nuclear staining for p-Erk 1/2 was 2.38
er visual field (median: 2.4; range: 0.0-4.20) and decreased
o 1.03 (median: 1.05; range: 0.00-2.75) after mechanical
upport (P  .001) (Figure 2, B). The mean count in the
ontrols was 0.13 (median: 0.03; range: 0.0-0.53); therefore,
lbeit significantly reduced, p-Erk 1/2 levels did not reach
he level of the controls after mechanical support as calcu-
ated by post hoc analysis.
By analyzing different regions of the myocardium
subepicardial, midmyocardial, and subendocardial), the
mmunoexpression of any of the parameters investigated
id not show a zonation (data not shown). In addition to
ardiomyocytes, immunoreactivity for COX-2, p-Akt (Thr308),
-Akt (Ser473), and Erk 1/2 was observed in endothelial and
ession of p-Akt (Ser473) (A) and p-Erk 1/2 (B) after LVAD
rences (horizontal bars). Note that p-Erk 1/2, although
controls (post hoc analysis according to Duncan).
hr308) protein expression (C) and COX-2 expression andexpr
t diffe
l of
kt (Tnflammatory cells and fibroblasts.
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Porrelation Between COX-2 and p-Akt (Thr308) Protein
xpression
significant positive correlation between the protein ex-
ression of COX-2 and p-Akt (Thr308) was noted in tissue
efore LVAD implantation, that is, in CHF (r  0.485; P 
01) (Figure 2, C). On investigation of selective, different
yocardial areas, this correlation was observed only in the
ubendocardial area (r  0.545; P  .01). However, no
orrelation between the 2 proteins was observed in tissues
btained after LVAD insertion. Moreover, there was no
orrelation between COX-2 and p-Akt (Ser473) or p-Erk ½
xpression before and after LVAD insertion.
orrelation Between COX-2 Expression and
ardiomyocyte Diameter
efore LVAD implantation, a significant positive correla-
ion between the protein expression of COX-2 and cardio-
yocyte diameter was demonstrated (r  0.420; P  .05)
Figure 2, D). No such correlation was observed after
VAD implantation. Moreover, a significant correlation
etween the decrease of COX-2–positive cardiomyocytes
nd the percentage of reduction of COX-2–positive cardio-
yocyte diameters was noted (r 0.421; P .05). No such
orrelation was found with COX-2–negative cardiomyo-
ytes. Furthermore, there was no correlation between the
xpression of p-Akt (Thr308)/(Ser473) or p-Erk 1/2 either before
r after LVAD implantation.
There was no correlation between the decrease of protein
xpression of COX-2 or p-Akt (Thr308) or between the de-
rease in cardiomyocyte diameter and the underlying cause
f CHF. Moreover, no differences in the decrease of the
arameters examined could be demonstrated depending on
he type of LVAD implanted. Furthermore, no differences
ith regard to the duration of the LVAD support and
ecrease of COX-2, p-Akt (Thr308), and cardiomyocyte di-
meters could be outlined (data not shown).
olocalization of COX-2 and p-Akt (Thr-308) in
ardiomyocytes
n a subset of cardiomyocytes, COX-2 and p-Akt (Thr308)
ould be detected in the same cell. In some cardiomyocytes
n overlay of fluorescein isothiocyanate and Cy3 signals
esulting in yellow signals was observed (online Figure 3,
-D). The majority of cardiomyocytes investigated ex-
ressed p-Akt (Thr308) or COX-2. After LVAD insertion,
olocalization of the proteins could scarcely be observed.
he controls did not show colocalization.
iscussion
consistent finding after LVAD insertion is a decrease in
ardiomyocyte diameters, length, and volume.4-6 A chronic
nflammatory process with induction of COX-2 contributing
o the progression of CHF could be outlined,10,11 suggesting
hat COX-2 is a key element in the inflammatory component a
The Journal of Thoracf CHF.12 Both COX-2 and Akt have been associated with
he progression of cardiac hypertrophy. In several animal
odels with COX-2 overexpression, in addition to hyper-
rophy, cardiac deterioration occurred and was improved by
OX-2 inhibitors, suggesting that COX-2 exerts cardiode-
ressive effects itself.17-19 Akt, which may function as an
pstream activator or downstream effector of the COX-2
ene, was found to regulate COX-2 transcription in vitro by
he increased activity of nuclear factor-kB, indicating that
kt is an upstream regulator.15 In contrast, one study on
epatocellular cancer cells described Akt phosphorylation
pecifically at Thr308 as a downstream signaling event
nduced by COX-2 overexpression. Phosphorylation of Akt
t Thr308 is a prerequisite for activation, whereas phosphor-
lation of Ser473 solely does not result in full activation.15
In the present study, there was a significant increase of
OX-2, p-Akt (both at Thr308 and Ser473), and p-Erk 1/2 in
ardiac tissue before LVAD support compared with con-
rols, and the levels of these parameters were significantly
ecreased after LVAD support. There are only limited data
oncerning changes of COX-2 expression on unloading.
azeghi and colleagues20 reported a lack of transcriptional
igure 3. Immunofluorescence doublestaining. Failing myocar-
ium before LVAD insertion: nuclei highlighted in blue (DAPI) (A).
-Akt (Thr308) highlighted in green (fluorescein isothiocyanate)
redominantly in the cardiomyocyte nuclei (green arrows) (B).
OX-2 highlighted in red by Cy-3 with granular cytoplasmic
istribution (red arrows) (C). Merged images demonstrating co-
ocalization and cytoplasmic overlay of COX-2 and p-Akt (Thr308) in
subset of cardiomyocytes (yellow arrows) (D).lterations of the COX-2 gene. In their study, none of the
ic and Cardiovascular Surgery ● Volume 133, Number 1 41
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CSPomponents of the PKB/Akt/GSK3 pathway were altered
y LVAD support, which is in contrast with our finding of
significant Akt decrease after LVAD support.21
The decrease of COX-2 protein expression in the present
tudy may be largely explained by the profound reduction of
olume/pressure load by LVAD normalizing wall tension,
hus altering the conditions that cause compensatory hyper-
rophy, including COX-2 and prostanoids. In the present
tudy only cardiomyocytes expressing COX-2 were en-
arged in CHF, but in contrast with COX-2–negative cardi-
myocytes, COX-2-positive cardiomyocytes showed signif-
cant hypertrophy regression on unloading. This finding and
he correlation between COX-2–positive cardiomyocytes
nd cardiomyocyte diameters give further emphasis to the
ypertrophic effect of COX-2, which can be reversibly
egulated by LVADs.
However, patients with LVADs receive acetylsalicylic
cid (100 mg) per day from the time of implantation. It must
e considered that some of the cellular and molecular
hanges observed during “reverse remodeling” may be af-
ected by drugs. Aspirin is the only nonsteroidal anti-
nflammatory drug that reacts covalently with the COX
omain of COX-1 and COX-2, resulting in permanent loss
f the COX activity.22 The antithrombotic effect of aspirin
s largely caused by the suppression of platelet TX A2
roduction by COX-1.23 However, much higher doses are
equired to affect COX-2 activity.24,25 The concentrations
sed in vitro are several orders of magnitude higher than the
oncentrations of aspirin in the serum, which indicates that
he changes found in our study are largely the result of
VAD treatment.
Furthermore, the correlations between COX-2 and
-Akt (Thr308), as well as COX-2 expression and cardio-
yocyte diameters before LVAD support, indicate that
oth proteins are involved in the regulation of cardiomy-
cyte hypertrophy in CHF.16 Moreover, these correla-
ions suggest a specific interaction between COX-2 and
-Akt (Thr308) through a thus unknown cross-talk between
hese 2 molecules in the progression of hypertrophy
uring CHF, which might be disrupted by left ventricular
upport. However, COX-2 and p-Akt Thr308 colocalize in
subset of cardiomyocytes before LVAD support, often
n the form of direct overlay in the cytoplasm, whereas
fter LVAD support this colocalization is hardly detect-
ble and controls are completely devoid of it. Thus, a
idely distributed direct interaction between the 2 pro-
eins obviously does not occur in every single cardiomy-
cyte. Akt phosphorylation by application of prostaglan-
in E2 analogues through the prostaglandin receptor EP2
as demonstrated in an intestinal cell line.26 Moreover,
OX-2-induced Akt activation through transactivation of
pidermal growth factor receptors by prostaglandin E2
as shown in vitro.27 Possibly in CHF, Akt activation is
2 The Journal of Thoracic and Cardiovascular Surgery ● Januanduced by similar autocrine or paracrine action of pros-
aglandins and their receptors in neighboring cardiomy-
cytes and/or fibroblasts. There was an overlay of
-Akt (Thr308) and COX-2 in some cardiomyocytes. As a
esult of lipofuscin removal by Sudan staining before-
and, autofluorescence is unlikely. Perhaps these signals
an be regarded as sites of interaction between the 2
roteins, probably mediated by additional molecules.
onclusions
his study demonstrates a negative regulation of COX-2,
-Akt (Thr308), p-Akt (Ser473), and p-Erk 1/2 protein expres-
ion and significant cardiac hypertrophy regression by
VAD support. Only COX-2–positive cardiomyocyte di-
meters were significantly decreased on unloading, suggest-
ng that the COX-2-mediated growth stimulus is confined
y the volume/pressure reduction by LVAD support and
hat the maladaptive hypertrophic response of cardiomyo-
ytes is finally abrogated. Moreover, a significant correla-
ion between both COX-2 and p-Akt (Thr308), as well as
OX-2 and cardiomyocyte hypertrophy, in CHF indicates a
hus unknown mechanism of hypertrophic cellular response,
hich might also be reversibly regulated by LVADs. Of
ote, COX-2, p-Akt, and p-Erk 1/2 decreased to near normal
evels, whereas cardiomyocyte diameters, albeit signifi-
antly reduced, remained higher than in controls, suggesting
hat in contrast with changes on the molecular level, hyper-
rophy is not fully reversible by LVADs. One of these
ypertrophic stimuli might be a molecular cross-talk be-
ween COX-2 and p-Akt Thr308, probably further mediated
y autocrine or paracrine mechanisms of prostaglandins
hroughout the myocardium. Eventually, activated Akt
ould then exert widespread influence on molecules in-
olved in cell growth and survival including p70S6-kinase,
TOR, Bad, and the Forkhead family of transcription fac-
ors. Given these observations, novel pharmacologic strate-
ies to manipulate both the COX-2 and PI3K/Akt pathway
eems desirable in the prevention of cardiac hypertrophy
uring CHF.
The skillful technical assistance of Ms Dorothe Möllmann and
r Peter Babioch is highly appreciated.
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